NEW ANTI-EPILEPTIC DRUG USAGE WHILE PREGNANT AND THE POSSIBILITY OF ADHD IN OFFSPRING

Main Article Content

Fatima Soomro
Dr Sangeet
Fnu Simran
Suresh Kumar
Jai Chand
Aisha Chohan

Keywords

Lamotrigine, Valproic acid, Pregnancy, Attention deficient hyperkinetic disorder (ADHD)

Abstract

Introduction: Three to seven out of every 1,000 expectant mothers suffer from epilepsy. Antiepileptic medicines (AEMs) are the mainstay of treatment. Many AEMs are related to neurodevelopmental defects in children when used by pregnant females. Objective: The current study examined the relationship between a mother's use of AEMs throughout her pregnancy and the likelihood that her unborn child may experience ADHD. Method The study's data came from babies born to epileptic mothers who received new anti-epileptic medications at any time during their pregnancy. From January 1, 2018, to December 31, 2019, we tracked babies born in our hospital, and we continued to make regular telephonic calls to assess their child status until December 31, 2023. Results ADHD was more prevalent in the babies of mothers belonging to the Valproic acid group, with incidence ranging up to 8.87%. The Lamotrigine group had a lower incidence of ADHD as compared to the Valproic acid group (5.71%). The lowest incidence was reported by the babies of mothers belonging to no anti-epileptic usage group (1.42%). Conclusion We found an association between maternal valproic acid use and an increased risk of ADHD. The results of the current investigation did not show any evidence linking the use of Lamotrigine during pregnancy to the onset of ADHD in the unborn child. We suggest that during pregnancy, Lamotrigine may not be as dangerous as other new anti-epileptic medications.

Abstract 110 | PDF Downloads 40

References

1. Birnbaum, A. K., Meador, K. J., Karanam, A., Brown, C., May, R. C., Gerard, E. E., Gedzelman, E. R., Penovich, P. E., Kalayjian, L. A., and Cavitt, J. (2020). Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA neurology 77, 441-450.
2. Błaszczyk, B., Miziak, B., Pluta, R., and Czuczwar, S. J. (2022). Epilepsy in pregnancy—management principles and focus on valproate—international journal of molecular sciences 23, 1369.
3. Cohen, M. J., Meador, K. J., Loring, D. W., Matthews, A. G., Brown, C., Robalino, C. P., Birnbaum, A. K., Voinescu, P. E., Kalayjian, L. A., and Gerard, E. E. (2024). Behavioral Outcomes and Neurodevelopmental Disorders Among Children of Women With Epilepsy. JAMA neurology 81, 19-29.
4. Daugaard, C. A., Pedersen, L., Sun, Y., Dreier, J. W., and Christensen, J. (2020). Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones. JAMA network open 3, e2025570-e2025570.
5. de Lima Leite, M., Toporcov, T. N., Pai, J. D., and da Silva, J. C. (2022). Socio-demographic profiles and obstetrics outcomes of pregnant women with epilepsy in a vulnerability State, Brazil. Plos one 17, e0271328.
6. Hu, T., Zhang, J., Wang, J., Sha, L., Xia, Y., Ortyl, T. C., Tian, X., and Chen, L. (2023). Advances in epilepsy: mechanisms, clinical trials, and drug therapies. Journal of Medicinal Chemistry 66, 4434-4467.
7. Kaplan, Y. C., and Demir, O. (2021). Use of phenytoin, phenobarbital carbamazepine, levetiracetam lamotrigine and valproate in pregnancy and breastfeeding: risk of major malformations, dose-dependency, monotherapy vs polytherapy, pharmacokinetics and clinical implications. Current neuropharmacology 19, 1805.
8. Laspro, M., Brydges, H. T., Verzella, A. N., Schechter, J., Alcon, A., Roman, A. S., and Flores, R. L. (2024). Association of Commonly Prescribed Antepartum Medications and Incidence of Orofacial Clefting. The Cleft Palate Craniofacial Journal, 10556656241237679.
9. Marxer, C. A., Rüegg, S., Rauch, M. S., Panchaud, A., Meier, C. R., and Spoendlin, J. (2021). A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy. Expert Opinion on Drug Safety 20, 1487-1499.
10. Meador, K. J., Cohen, M. J., Loring, D. W., May, R. C., Brown, C., Robalino, C. P., Matthews, A. G., Kalayjian, L. A., Gerard, E. E., and Gedzelman, E. R. (2021). Two-year-old cognitive outcomes in children of pregnant women with epilepsy in the maternal outcomes and neurodevelopmental effects of antiepileptic drugs study. JAMA neurology 78, 927-936.
11. Pennell, P. B., Karanam, A., Meador, K. J., Gerard, E., Kalayjian, L., Penovich, P., Matthews, A., McElrath, T. M., Birnbaum, A. K., and Cohen, M. (2022). Antiseizure medication concentrations during pregnancy: results from the maternal outcomes and neurodevelopmental effects of antiepileptic drugs (MONEAD) study. JAMA neurology 79, 370-379.
12. Peron, A., Picot, C., Jurek, L., Nourredine, M., Ripoche, E., Ajiji, P., Cucherat, M., and Cottin, J. (2024). Neurodevelopmental outcomes after prenatal exposure to lamotrigine monotherapy in women with epilepsy: a systematic review and meta-analysis. BMC Pregnancy and Childbirth 24, 103.
13. Reynolds, E. H., and Green, R. (2020). Valproate and folate: Congenital and developmental risks. Epilepsy & Behavior 108, 107068.
14. Sharma, A. R., Batra, G., Saini, L., Sharma, S., Mishra, A., Singla, R., Singh, A., Singh, R. S., Jain, A., and Bansal, S. (2022). Valproic acid and propionic acid modulated mechanical pathways associated with autism spectrum disorder at prenatal and neonatal exposure. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 21, 399-408.
15. Shimizu, H., Morimoto, Y., Yamamoto, N., Tayama, T., Ozawa, H., and Imamura, A. (2022). Overlap between epilepsy and neurodevelopmental disorders: insights from clinical and genetic studies. Exon Publications, 41-54.
16. Veroniki, A. A., Cogo, E., Rios, P., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., and Hutton, B. (2017). Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC medicine 15, 1-20.
17. Yeh, T.-C., Bai, Y.-M., Hsu, J.-W., Huang, K.-L., Tsai, S.-J., Chu, H.-T., Liang, C.-S., and Chen, M.-H. (2021). Bipolar women's antepartum psychotropic exposure and offspring risk of attention-deficit/hyperactivity disorder and autism spectrum disorder. Journal of Affective Disorders 295, 1407-1414.

Most read articles by the same author(s)